Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Damoctocog alfa pegol - Bayer HealthCare Pharmaceuticals

Drug Profile

Damoctocog alfa pegol - Bayer HealthCare Pharmaceuticals

Alternative Names: Antihemophilic factor [recombinant] PEGylated-aucl; BAY-949027; Damoctocog alfa pegol; Jivi; peg rFVIII; PEG rFVIII mutein; PEGylated B-Domain-Delted Recombinant rFVIII; PEGylated BDD-rFVIII; rFVIII glycopegylated

Latest Information Update: 02 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Haemophilia A; Haemorrhage

Most Recent Events

  • 05 Dec 2018 Adverse events and efficacy data from PROTECT VIII Extension trial in Haemophilia A presented at the 60th American Society of Hematology Annual Meeting (ASH-Hem-2018)
  • 01 Dec 2018 Updated efficacy data from PROTECT VIII Extension trial in Haemophilia A presented at the 60th American Society of Haematology Annual Meeting (ASH-Hem-2018)
  • 27 Nov 2018 Registered for Haemophilia A (In adolescents, Treatment-experienced, In adults) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top